Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


TopoTarget A/S Acquires G2M Cancer Drugs AG


Copenhagen, DK and Oxford, UK … 1 March 2005 –TopoTarget A/S has acquired G2M Cancer Drugs AG (G2M), the German anti-cancer therapeutics company. The move unites two companies with complementary strategies, products and research and creates a heavy weight Danish oncology company with subsidiaries in the UK and Germany. The new entity will be a leader in the field of histone deacetylase (HDAC) inhibitors, have a broad and rich development portfolio and the potential to reach sustainable profitability by 2007.

G2M’s oncology portfolio includes two products based on the histone deacetylase (HDAC) inhibitor, G2M-777. BACECA® is currently in Phase II clinical evaluation and PEAC® is anticipated to enter Phase II later this year. Its third product, ZEMAB®, has just completed Phase I clinical trials.

Dr Peter Buhl Jensen, MD, PhD, CEO of TopoTarget commented 'G2M is an excellent strategic fit. The two companies have complementary products, research interests and objectives, which centre on developing novel cancer therapies and new oncology indications for existing drugs.”

“This deal broadens and strengthens our clinical and preclinical pipeline. In particular, G2M-777 complements TopoTarget’s HDAC inhibitor PXD101, to give TopoTarget a commanding position in this important area of oncology. TopoTarget is developing PXD101 in collaboration CuraGen Corporation (NASDAQ:CRGN) and it recently entered Phase II clinical trials in patients with the serious blood cancer, advanced multiple myeloma. Closer to market is Topotect, TopoTarget’s therapy for the prevention of severe tissue damage following accidental extravasation of chemotherapeutics, which is in Phase III clinical trials and scheduled for launch in 2006. We are also developing Topotect/etoposide, a co-therapy for the treatment of patients with brain metastasis, which is in Phase I clinical trials.

In detail, the G2M clinical portfolio includes:
** PEAC® – an anticancer therapy product based on a small molecule, G2M-777, which functions as a histone deacetylase (HDAC) inhibitor. G2M has successfully developed a novel proprietary galenic formulation of this compound, which selectively inhibits a key subset of HDAC isoenzymes implicated in cancer. It is anticipated that PEAC® will enter Phase II evaluation in 2005, in patients with a genetic predisposition to develop colon cancer. G2M has been granted Orphan Medicinal Product Designation in Europe for PEAC® in this indication.

** BACECA® – a novel topical therapeutic form of G2M-777 for hyperproliferative skin diseases, such as cancerous and precancerous skin lesions and inflammatory disorders. The therapy has entered a Phase II clinical trial in patients with an inflammatory skin disease. In addition, the company plans to begin further Phase II clinical trials in patients with skin cancer later this year.

** ZEMAB® – An antibody based compound which targets a common cancer antigen and which is relevant to breast, head and neck cancer patients for example. ZEMAB® has successfully completed Phase I clinical trials.

G2M’s drug discovery platform HYACETECH® supports the identification of novel HDAC inhibitors. In addition, it has an extensive range of preclinical projects, which aim to address cancer cell invasion and survival, tumour marker identification and function elucidation.

G2M was founded in March 2001. Its headquarters are in Frankfurt and its research and development centres are based at the Georg-Speyer-Haus Institute for Biomedical Research in Frankfurt and at the Institute of Toxicology and Genetics at the Research Centre, Karlsruhe. In November 2004, G2M received the Healthcare Competency Award 2004 in recognition of its development strategy and business model. Dr Thomas Borcholte and Dr Bernd Hentsch, Executive Board members at G2M, will join TopoTarget as Chief Marketing and Sales Officer and as Director International Project Management respectively. G2M will be a wholly owned subsidiary of Topo


Publisher Contact Information:

TopoTarget
+45 39 17 83 92
enquiries@topotarget.com

Company profile of TopoTarget
Past press releases of TopoTarget.

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.